Merck to buy Prometheus Biosciences for about $11 billion
Economy And Jobs,Pharmaceuticals,Big Pharma,Banking And Finance,Acquisitions
From the Center
AllSides Media Bias Rating: Center
Merck & Co (MRK.N) has agreed to acquire Prometheus Biosciences Inc (RXDX.O) for about $10.8 billion to bolster the company's presence in immunology, the companies said on Sunday.
The joint statement said that Merck, through one of its subsidiaries, will pay $200 per share for the biotechnology company that specializes in products for treatment of immunological diseases. That represents a 75% premium to the $114.01 closing price for Prometheus shares on Friday.
Check for Bias
The AI-powered AllSides Bias Checker instantly reveals the bias of a news article. Tap the button to use.
Related Coverage
AllSides Picks
Headline Roundup
Laid Off Meta Employees Sue Company for Using AI to Target Workers Who Took Leave
July 16th, 2026
.webp)
Red Blue Translator
